FDA grants Priority Review to Gilotrif for uncommon EGFR mutations in advanced NSCLC Epidermal Growth Factor Receptor (EGFR), Mutations, Non-Small Cell Lung Cancer (NSCLC), Priority Review, supplemental New Drug Applications (sNDA) Boehringer Ingelheim announced that the supplemental New Drug Application for Gilotrif (afatinib) was accepted for filing and granted Priority Review by the U.S. Food and Drug Administration. Read more October 10, 2017/by PR Newswire https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png 0 0 PR Newswire https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png PR Newswire2017-10-10 09:00:382017-10-10 12:55:55FDA grants Priority Review to Gilotrif for uncommon EGFR mutations in advanced NSCLC
